Lexaria Bioscience Corp.
LEXX · NASDAQ
8/31/2025 | 8/31/2024 | 8/31/2023 | 8/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.03 | 0.16 | 0.06 | -0.07 |
| FCF Yield | -65.96% | -10.33% | -87.13% | -28.76% |
| EV / EBITDA | -1.19 | -7.41 | -0.90 | -1.79 |
| Quality | ||||
| ROIC | -438.07% | -73.79% | -229.74% | -85.68% |
| Gross Margin | 99.61% | 98.96% | 86.07% | 71.87% |
| Cash Conversion Ratio | 0.88 | 0.85 | 0.88 | 0.66 |
| Growth | ||||
| Revenue 3-Year CAGR | 46.13% | 22.05% | -32.10% | -6.73% |
| Free Cash Flow Growth | -108.92% | 17.33% | -20.76% | -23.14% |
| Safety | ||||
| Net Debt / EBITDA | 0.14 | 1.12 | 0.19 | 0.88 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 1.87 |
| Cash Conversion Cycle | 190.46 | -27,988.10 | -2,324.81 | 352.25 |